• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Antiphosphatidylserine/prothrombin (aPS/PT) antibodies are associated with Raynaud phenomenon and migraine in primary thrombotic antiphospholipid syndrome.
Conclusions In PAPS patients aPS/PT antibodies are related to the occurrence of both Raynaud phenomenon and migraine. PMID: 29338587 [PubMed - as supplied by publisher]
Source: Lupus - January 1, 2018 Category: Rheumatology Authors: Kopytek M, Natorska J, Undas A Tags: Lupus Source Type: research

Large Artery Dysfunction in Primary Antiphospholipid Syndrome
Conclusions The higher b/a ratio in APL patients suggests decreased distensibility of large arteries and may be why APL patients are at higher risk for cardiovascular events. The d/a ratio, that is considered a marker of small vessel vascular resistance, was not different than controls. Further studies are needed to evaluate vascular factors that predispose APL patients to atherosclerotic events.
Source: JCR: Journal of Clinical Rheumatology - December 24, 2017 Category: Rheumatology Tags: Original Articles Source Type: research

Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: a database prospective cohort study
ConclusionLong-term HCQ appears to have no vascular protective effect in patients with SLE.
Source: Rheumatology - September 27, 2017 Category: Rheumatology Source Type: research

Subclinical myocardial dysfunction by tissue Doppler echocardiography in primary antiphospholipid syndrome: Preliminary results
Conclusion The present study demonstrated subclinical myocardial dysfunction using TDI in asymptomatic PAPS patients. TDI is non-invasive and cost effective. Prospective studies including a large number of participants in order to confirm these preliminary data are needed.
Source: The Egyptian Rheumatologist - June 20, 2017 Category: Rheumatology Source Type: research

Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study
To investigate the risk of first-time acute coronary syndrome (ACS), stroke and venous thromboembolism (VTE) in patients with ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated spondyl...
Source: Arthritis Research and Therapy - May 18, 2017 Category: Rheumatology Authors: Karin Bengtsson, Helena Forsblad-d ’Elia, Elisabeth Lie, Eva Klingberg, Mats Dehlin, Sofia Exarchou, Ulf Lindström, Johan Askling and Lennart T. H. Jacobsson Source Type: research

Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis?
Conclusions Prevalent patients with AS are at a 30%–50% increased risk of incident CV events. When compared with patients with RA, this level of increase was similar for stroke, but only half as high for ACS and thrombotic events.
Source: Annals of the Rheumatic Diseases - January 9, 2017 Category: Rheumatology Authors: Eriksson, J. K., Jacobsson, L., Bengtsson, K., Askling, J. Tags: Immunology (including allergy), Ankylosing spondylitis, Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis, Calcium and bone Clinical and epidemiological research Source Type: research

Hyperuricemia in systemic lupus erythematosus: is it associated with the neuropsychiatric manifestations of the disease?
Conclusions: Hyperuricemia in SLE patients is independently associated with the occurrence of stroke and peripheral neuropathy. It is also independently associated with hypertension, hyperlipidemia, and history of arterial thrombosis, which are the major stroke and myocardial infarction risk factors in SLE patients.RESUMO Objetivos: Avaliar a associa ção entre a hiperuricemia e diferentes manifestações neuropsiquiátricas e os fatores de risco para AVE em pacientes com lúpus eritematoso sistêmico (LES). Métodos: Este estudo foi feito em 204 pacientes com LES que foram internados em um centro de referência de atenç...
Source: Revista Brasileira de Reumatologia - December 20, 2016 Category: Rheumatology Source Type: research

Rivaroxaban 'could be a safe treatment option for antiphospholipid syndrome'
The drug rivaroxaban could be an effective means of treating some patients with thromboticantiphospholipid syndrome, according to a new study. Led by University College London and funded byArthritis Research UK, the research has suggested that the drug - which works by inhibiting the formation of blood clots - could be a useful tool in the treatment of those with this serious condition, which affects approximately 15 per cent of patients withlupus and may also occur on its own. The danger of antiphospholipid syndrome Thrombotic antiphospholipid syndrome is classified as a rare condition, but is probably underdiagnosed. It ...
Source: Arthritis Research UK - August 29, 2016 Category: Rheumatology Source Type: news

Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?
Abstract Antiphospholipid syndrome (APS) is characterized by arterial and/or venous thrombosis with or without pregnancy morbidity in the presence of autoantibodies targeting proteins that associate with membrane phospholipids, termed “antiphospholipid antibodies” (aPL). Management of arterial and venous thromboses shares some similarities with management of arterial and venous thromboses in the general population; however, there are key differences. The majority of studies addressing management of thrombotic APS focus on secondary prevention. Vitamin K antagonists (VKA) are typically used for secondary preve...
Source: Current Rheumatology Reports - March 30, 2016 Category: Rheumatology Source Type: research

Clinical Image: Mitral Valve Vegetation in Antiphospholipid Syndrome
This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatism - January 27, 2016 Category: Rheumatology Authors: Ozan Unlu, Sarah B. Lieber, Mary J. Roman, Doruk Erkan, Michael D. Lockshin Tags: Clinical Image Source Type: research

The impact of inflammatory rheumatic diseases on the presentation, severity, and outcome of acute coronary syndrome
Abstract Patients with inflammatory rheumatic diseases (IRD) have a high burden of cardiovascular disease (CVD), leading to increased mortality and morbidity. However, it is not clear whether increased CVD mortality in IRD is due to a higher incidence or worse outcome of cardiovascular events (higher case fatality). In this observational case–control study, we assessed the outcome of acute coronary syndrome (ACS) in patients with IRDs compared to matched controls without IRD, using data from the Acute Coronary Syndrome Israeli Survey (ACSIS), a large, national, real-life registry detailing the extent, severity,...
Source: Clinical Rheumatology - January 1, 2016 Category: Rheumatology Source Type: research

Hyperuricemia in systemic lupus erythematosus: is it associated with the neuropsychiatric manifestations of the disease?
Conclusions Hyperuricemia in SLE patients is independently associated with the occurrence of stroke and peripheral neuropathy. It is also independently associated with hypertension, hyperlipidemia, and history of arterial thrombosis, which are the major stroke and myocardial infarction risk factors in SLE patients.
Source: Revista Brasileira de Reumatologia - August 11, 2015 Category: Rheumatology Source Type: research

Inpatient complications in patients with giant cell arteritis: decreased mortality and increased risk of thromboembolism, delirium and adrenal insufficiency
Conclusion: Hospitalized GCA patients have lower mortality compared with the general inpatient population but greater risk of venous thromboembolism, delirium and adrenal insufficiency.
Source: Rheumatology - July 14, 2015 Category: Rheumatology Authors: Unizony, S., Menendez, M. E., Rastalsky, N., Stone, J. H. Tags: Vasculitis CLINICAL SCIENCE Source Type: research

Using New Oral Anticoagulants in Patients Undergoing Major Orthopedic Surgery
Abstract Four new oral anticoagulants (NOAC), apixaban, rivaroxaban, edoxaban, and dabigatran, are now available in the USA; however, only apixaban and rivaroxaban are FDA approved for the prevention of venous thromboembolism following orthopedic surgery. Apixaban, rivaroxaban, and edoxaban’s anticoagulant activity can be measured using a chromogenic anti-factor Xa assay but there is no widely available means of measuring dabigatran blood levels. None of the NOAC has an antidote. Dabigatran is 80 % renally excreted, and patients with atrial fibrillation taking dabigatran for stroke prevention should stop the d...
Source: Current Rheumatology Reports - April 8, 2015 Category: Rheumatology Source Type: research

Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS).
CONCLUSION: This study demonstrates content, criterion and construct validity of a new physician-reported instrument to assess the DIAPS. In addition, the DIAPS correlated with the EuroQol. PMID: 25767071 [PubMed - as supplied by publisher]
Source: Lupus - March 11, 2015 Category: Rheumatology Authors: Amigo MC, Goycochea-Robles MV, Espinosa-Cuervo G, Medina G, Barragán-Garfias JA, Vargas A, Jara LJ Tags: Lupus Source Type: research

Pages: 1  2  3  4